ArticleBMC nephrology2026
Chronic kidney disease and reduced renal COX2 expression in xanthinuria: a case-control study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundXanthinuria is a rare inherited metabolic disorder caused by xanthine dehydrogenase (XDH) deficiency, leading to excessive urinary xanthine excretion. It is associated with kidney stones and, in exceptional cases, renal failure. To date, no kidney biopsy findings have been reported in cases of xanthinuria. We present the first documented biopsy from such a patient, revealing a reduction in cyclooxygenase-2 (COX2) expression. CASE PRESENTATION: A 38-year-old man of Afghan origin presented with flank pain and a staghorn calculus in the right kidney. Laboratory tests revealed impaired renal function with serum creatinine at 192 µmol/L. Percutaneous nephrolithotomy was performed to remove the stone, and infrared analysis confirmed its 100% xanthine composition. Genetic sequencing identified two pathogenic variants in the XDH gene, confirming type I xanthinuria. Despite stone removal, renal function progressively declined during the following months, with serum creatinine reaching 238 µmol/L and significant albuminuria. Imaging revealed no residual stones or atrophy of the right kidney, while the left kidney remained free of lithiasis. A biopsy of the left kidney demonstrated advanced chronic kidney disease with fibrosis, without crystal deposits or stones. As the etiology of nephropathy remained unclear, we assessed COX2 expression, an enzyme involved in prostaglandin synthesis, in the left kidney tissue. Compared with healthy controls and biopsies from other advanced chronic kidney disease cases, the xanthinuria biopsy showed considerably reduced tubular COX2 expression. The patient ultimately developed end-stage renal failure at age 41 and underwent successful kidney transplantation, achieving excellent graft function 32 months post-transplant.
conclusionsThis case provides the first histopathological evidence of chronic kidney disease in xanthinuria without crystal deposition and identifies reduced tubular COX2 expression as a potential pathogenic mechanism. These findings support hypotheses from animal models suggesting that xanthine dehydrogenase deficiency may impair prostaglandin synthesis, contributing to kidney fibrosis and possibly abnormal nephrogenesis. Further investigation of similar cases could improve our understanding of rare metabolic disorders and inform strategies to preserve kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.